Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Sell
25
CSTL Quote, Financials, Valuation and Earnings
Last price:
$27.63
Seasonality move
:
-4.36%
Day range:
$27.15 - $27.85
52-week range:
$16.97 - $35.84
Dividend yield:
0%
P/E ratio:
130.86x
P/S ratio:
2.48x
P/B ratio:
1.75x
Volume:
207.4K
Avg. volume:
335.8K
1-year change:
27.05%
Market cap:
$769.6M
Revenue:
$219.8M
EPS (TTM):
$0.21
Analysts' Opinion
-
Consensus RatingCastle Biosciences has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $41.56, Castle Biosciences has an estimated upside of 51.22% from its current price of $27.48.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $36.00 representing 100% downside risk from its current price of $27.48.
Fair Value
-
According to the consensus of 8 analysts, Castle Biosciences has 51.22% upside to fair value with a price target of $41.56 per share.
CSTL vs. S&P 500
-
Over the past 5 trading days, Castle Biosciences has underperformed the S&P 500 by -6.21% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Castle Biosciences does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Castle Biosciences has grown year-over-year revenues for 15 quarters straight. In the most recent quarter Castle Biosciences reported revenues of $85.8M.
Earnings Growth
-
Castle Biosciences has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Castle Biosciences reported earnings per share of $0.08.
Enterprise value:
499.9M
EV / Invested capital:
1.11x
Price / LTM sales:
2.48x
EV / EBIT:
43.00x
EV / Revenue:
1.60x
PEG ratio (5yr expected):
--
EV / Free cash flow:
14.47x
Price / Operating cash flow:
22.41x
Enterprise value / EBITDA:
19.93x
Gross Profit (TTM):
$255.4M
Return On Assets:
1.29%
Net Income Margin (TTM):
1.95%
Return On Equity:
1.49%
Return On Invested Capital:
1.46%
Operating Margin:
5.92%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $123.7M | $192M | $311.9M | $61.5M | $85.8M | |
| Gross Profit | $96.7M | $149.9M | $255.4M | $50.2M | $70.2M | |
| Operating Income | -$83.2M | -$85.5M | -$1M | -$9.6M | $5.1M | |
| EBITDA | -$54.3M | -$63.4M | $25.1M | -$3.7M | $12M | |
| Diluted EPS | -$2.05 | -$2.84 | $0.21 | -$0.26 | $0.08 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $201.1M | $389.6M | $299.4M | $279.6M | $344.8M | |
| Total Assets | $210.4M | $433.7M | $457.8M | $436M | $514.6M | |
| Current Liabilities | $30.2M | $21M | $31.9M | $36.3M | $44.3M | |
| Total Liabilities | $43.8M | $22M | $46.4M | $50.2M | $73.5M | |
| Total Equity | $166.6M | $411.7M | $411.4M | $385.8M | $441.1M | |
| Total Debt | $22.5M | -- | -- | -- | $10M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$38.4M | -$30.2M | $59.1M | $5M | $23.3M | |
| Cash From Investing | -$193M | -$13M | -$63.6M | -$9.7M | -$14.8M | |
| Cash From Financing | $2.4M | $249K | $8.2M | $45K | $838K | |
| Free Cash Flow | -$43.2M | -$41.8M | $34.5M | $2.6M | $17M | |
CSTL
Sector
Market Cap
$769.6M
$45.6M
Price % of 52-Week High
76.67%
45.55%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
27.05%
-31.35%
Beta (5-Year)
0.919
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$27.94
200-day SMA
Buy
Level
$25.59
Bollinger Bands (100)
Sell
Level
27.26 - 32.18
Chaikin Money Flow
Buy
Level
7.7M
20-day SMA
Sell
Level
$29.59
Relative Strength Index (RSI14)
Sell
Level
37.89
ADX Line
Buy
Level
13.78
Williams %R
Buy
Level
-81.2698
50-day SMA
Sell
Level
$31.00
MACD (12, 26)
Sell
Level
-0.95
25-day Aroon Oscillator
Sell
Level
-32
On Balance Volume
Neutral
Level
13.2M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (5.7672)
Buy
CA Score
(Annual)
Level (0.8856)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Buy
Ohlson Score
Level (-0.2464)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.
Stock Forecast FAQ
In the current month, CSTL has received 8 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CSTL average analyst price target in the past 3 months is $41.56.
-
Where Will Castle Biosciences Stock Be In 1 Year?
According to analysts, the consensus estimate is that Castle Biosciences share price will rise to $41.56 per share over the next 12 months.
-
What Do Analysts Say About Castle Biosciences?
Analysts are divided on their view about Castle Biosciences share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Castle Biosciences is a Sell and believe this share price will drop from its current level to $36.00.
-
What Is Castle Biosciences's Price Target?
The price target for Castle Biosciences over the next 1-year time period is forecast to be $41.56 according to 8 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CSTL A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Castle Biosciences is a Buy. 8 of 8 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CSTL?
You can purchase shares of Castle Biosciences via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Castle Biosciences shares.
-
What Is The Castle Biosciences Share Price Today?
Castle Biosciences was last trading at $27.63 per share. This represents the most recent stock quote for Castle Biosciences. Yesterday, Castle Biosciences closed at $27.48 per share.
-
How To Buy Castle Biosciences Stock Online?
In order to purchase Castle Biosciences stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
73
PSIX alert for Dec 24
Power Solutions International [PSIX] is up 27.42% over the past day.
Sell
40
MSTR alert for Dec 24
MicroStrategy [MSTR] is up 8.07% over the past day.
Sell
26
NUTX alert for Dec 24
Nutex Health [NUTX] is down 1.39% over the past day.
